A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

Exclusion Criteria

• •Previous positive test for SARS-CoV-2
• •Previous positive serology test for SARS-CoV-2
• •Live in a skilled nursing facility with COVID-19 symptoms (Temp \>38 C in addition to sore throat, cough, wheezing, chest tightness, shortness of breath, body aches or chills, diarrhea, anosmia)
• •Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives
• •Pre-existing retinopathy
• •Known chronic kidney disease, stage 4 or 5, or receiving dialysis
• •Breast Feeding
• •Tamoxifen
• •Absolute neutrophil Count \<1,000/ml at registration
• •Concurrent use of any other quinine derivative
• •Antiarrhythmic medications: amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide
• •Glucose-6-phosphate dehydrogenase deficiency
• •Pre-treatment corrected QT interval (QTc) ≥470 milliseconds\*\*
• •Prisoners
• •Inability to participate
• •Psoriasis
• •History of suicidal ideation
• •COVID-19 Atypical Features
• •* Isolated lobar or segmental consolidation without GGO
• •* Discrete small nodules (centrilobular, "tree-in-bud")
• •* Lung cavitation
• •* Smooth interlobular septal thickening with pleural effusion
• •COVID-19 Indeterminate Features
• •* Multifocal, diffuse, perihilar, or unilateral GGO with or without consolidation lacking a specific distribution and are non-rounded or non-peripheral
• •* Few very small GGO with a non-rounded and non-peripheral distribution
• •COVID-19 Typical Features
• •* Peripheral, bilateral GGO with or without consolidation or visible intralobular lines ("crazy paving")
• •* Multifocal GGO of rounded morphology with or without consolidation or visible intralobular lines ("crazy paving")
• •* Reverse Halo sign or other findings of organizing pneumonia \*\* If pre-treatment QTC can be decreased to \<470, the patient can be re-considered for trial.